

Table S1. Study characteristics.

| Study | Study Design | No. of patients | Age (years) | No. of implants | Approach | F/U periods |
|-----------------------------|--------------------------------|--------------------|--------------------------------|---|-----------|-----------------------|
| Acocella et al. 2010 | Prospective study | 68 (37M 31F) | 29.19±3.62 | 68 | One-stage | 3 years |
| Aguirre-Zorzano et al. 2011 | Prospective clinical study | 57 (19M 37F) | 26-78 | 78 (56 after extraction and 22 in healed sockets) | One-stage | 92 weeks |
| Andreasi Bassi et al. 2016 | Prospective clinical study | 52 (31M 21F) | 54±11 | 52 | One-stage | 44.6±34.4 months |
| Arora et al. 2017 | Prospective study | 30 (9M 21F) | 20-78 | 30 | One-stage | 2-5 years |
| Atieh et al. 2013 | Controlled clinical trial | 24 (IIP12, DIP12) | IIP 51.5±13.4 DIP 53.6±12.3 | 24 (IIP12, DIP12) | Two-stage | 1 year |
| Baer et al. 2013 | Prospective, multicenter study | 84 (37M 47F) | 53.23±12.6 | 115 | One-stage | 6 months to 3 years |
| Baer et al. 2013 | Prospective study | 84 (37M 47F) | 53.23±2.67 | 115 | One-stage | 6 months to 3 years |
| Canullo et al. 2010 | Randomized Clinical Trial | 25 | 42-68 | 25 | Two-stage | 3 years |
| Carinci 2012 | Retrospective cohort study | 19 (9M 10 F) | 65±11 | 36 Opi (Diamond; BIOIMPLANT, Milan, Italy) | One-stage | 7 months |
| Cooper et al. 2014 | Prospective study | 113 (IIP55, DIP58) | IIP 45±14 DIP 42±15 | 113 (IIP55, DIP58) | Two-stage | 5 years |
| Corvino et al. 2020 | Randomized Clinical Trial | 33 (17M 16F) | 67.4±14.5 | 53 in the maxilla 15 in the mandible | Two-stage | 6 months to 1 year |
| Cosyn et al. 2011 | Prospective study | 30 (14M 16F) | 24-76 | 30 | One-stage | 3 years |
| Covani et al. 2012 | Prospective Cohort Study | 91 (36M 55F) | 23-75 | 159 | One-stage | 10 years |
| Cucchi et al. 2017 | Randomized Clinical Trial | 92 (43M 49F) | 51.0±9.5 | 97 | Two-stage | 3 years |
| Esposito et al. 2015 | Randomized Clinical Trial | 106 (46M 60F) | 28-72 | 106 | Two-stage | 4 months to 12 months |

| | | | | | | |
|------------------------|---|---|--------------------------------|---|-----------|----------------------------------|
| Felice et al. 2015 | Randomized Clinical Trial | 50 | ND | 50 | Two-stage | 4 months to 12 months |
| Gamper et al. 2017 | Randomized controlled clinical trial | 60 (S1: 13 M17F; S2: 10M 20F) | S1 47.5±15 S2 55.8±14 | 151 one-piece (Straumann tissue-level implants, Institut Straumann, Basel, Switzerland; S1) or two-piece dental implants (Bränemark MkIII or MkIV, Nobel Biocare, Zurich, Switzerland; S2). | Two-stage | 4-6 years |
| Guarnieri et al. 2015 | Prospective study | 21 (14M 7F) | 22-40 | 21 | One-stage | 5 years |
| Mangano et al. 2013 | Retrospective study | 40 | 45-47 | 40 | Two-stage | 34.44±7.10 months |
| Meijer et al. 2019 | Prospective study | 40 | 18-66 | 40 | One-stage | 12 months |
| Meloni et al. 2020 | Randomized controlled trial | 18 | ND | 36 | One-stage | 12 years (3 months to 60 months) |
| Naeini et al. 2018 | Prospective study | 49 | 62±12.9 | 53 (TiUnite Bränemark implants) | One-stage | 6-9 years (88 months) |
| Negri et al. 2014 | Longitudinal analysis of a consecutive series (Controlled Clinical Trial) | 252 | 54.4±0.7 | 632 (ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length.) | Two-stage | 36 months (3 years) |
| Oliver 2012 | Controlled Clinical Trial | 241 (108M 133F) | 19-73 | 432 (Osstem GSII bone level implants) | One-stage | 12 months |
| Raes et al. 2016 | Randomized Clinical Trial | 96 (41M 55F) | 43±14.8 | 102 | Two-stage | 5 years |
| Raes et al. 2018 | prospective study | IIP16 DIP23 | IIP45 DIP40 | IIP16 DIP23 | Two-stage | 96 months |
| Tonetti et al. 2017 | Randomized Controlled Clinical Trial | 124 | 55±13 | 124 | Two-stage | 1 year to 3 years |
| Zuiderveld et al. 2018 | Randomized Clinical Trial | 60 (28M32F) | 19.5-82.2 | 60 | One-stage | 12 months |

Table S2. Implant success rate.

| Study | No. of implants | Approach | F/U periods | Success rate (%) |
|----------------------------|---|-----------|--------------------------|---|
| Andreasi Bassi et al. 2016 | 52 | One-stage | 44.6±34.4 months | 77% |
| Baer et al. 2013 | 115 | One-stage | 6 months to 3 years | 100% |
| Canullo et al. 2010 | 25 | Two-stage | 3 years | 100% |
| Carinci 2012 | 36 | One-stage | 7 months | 91.7% |
| Corvino et al. 2020 | 53 in the maxilla 15 in the mandible | Two-stage | 6 months to 1 year | 100% |
| Cosyn et al. 2011 | 30 | One-stage | 3 years | 76% |
| Covani et al. 2012 | 159 | One-stage | 10 years | 91.8% (87.9% in the non-GBR group and 94.1% in the GBR group) |
| Esposito et al. 2015 | 106 | Two-stage | 4 months to 12 months | 100% |
| Mangano et al. 2013 | 40 | Two-stage | 34.44±7.10 | 100% |
| Meloni et al. 2020 | 36 | One-stage | 5 years | 100% |
| Naeini et al. 2018 | 53 | One-stage | 6-9 years (88 months) | 100% |
| Negri et al. 2014 | 632 | Two-stage | 36 months | 100% |
| Oliver 2012 | 432 | One-stage | 12 months | 100% |
| Tonetti et al. 2017 | 124 | Two-stage | 1 year to 3 years | 100% |
| Zuiderveld et al. 2018 | 60 | One-stage | 12 months | 96.7% |

Table S3. Implant survival rate.

| Study | No. of implants | Approach | F/U periods | Survival rate |
|-----------------------------|-----------------|-----------|---------------------|------------------------|
| Acocella et al. 2010 | 68 | One-stage | 3 years | 97.96% |
| Aguirre-Zorzano et al. 2011 | 78 | One-stage | 92 weeks | 98.7% |
| Andreasi Bassi et al. 2016 | 52 | One-stage | 44.6±34.4 months | 100% |
| Arora et al. 2017 | 30 | One-stage | 2-5 years | 100% |
| Atieh et al. 2013 | 24 | Two-stage | 1 year | IIP 66.7% DIP 83.3% |
| Baer et al. 2013 | 115 | One-stage | 6 months to 3 years | 98.3% |

| | | | | |
|------------------------|---|-----------|--------------------------|---|
| Baer et al. 2013 | 115 | One-stage | 6 months to 3 years | 98.3% |
| Canullo et al. 2010 | 25 | Two-stage | 3 years | 100% |
| Carinci 2012 | 36 | One-stage | 7 months | 97% |
| Cooper et al. 2014 | 113 (IIP55 DIP58) | Two-stage | 5 years | IIP 94.5% DIP 98.3% |
| Corvino et al. 2020 | 53 in the maxilla 15 in the mandible | Two-stage | 6 months to 1 year | 100% |
| Cosyn et al. 2011 | 30 | One-stage | 3 years | 96% |
| Covani et al. 2012 | 159 | One-stage | 10 years | 91.8% |
| Cucchi et al. 2017 | 97 | Two-stage | 3 years | 95.9% ~ 100% |
| Esposito et al. 2015 | 106 | Two-stage | 4 months to 12 months | 100% |
| Felice et al. 2015 | 50 | Two-stage | 4 months to 12 months | 100% |
| Gamper et al. 2017 | 151 one-piece (S1) or two-piece dental implants (S2) | One-stage | 4-6 years | 97.9% (S1: 96.6% S2: 98.9%) (P = 0.592). |
| Guarnieri et al. 2015 | 21 | One-stage | 5 years | 95.2% |
| Mangano et al. 2013 | 40 | Two-stage | 34.44±7.10 | 100% |
| Meijer et al. 2019 | 40 | One-stage | 12 months | 100% |
| Meloni et al. 2020 | 36 | One-stage | 5 years | 100% |
| Naeini et al. 2018 | 53 | One-stage | 6-9 years (88 months) | 100% |
| Negri et al. 2014 | 632 | Two-stage | 36 months | 98.73%. |
| Oliver 2012 | 432 | One-stage | 12 months | 100% |
| Raes et al. 2016 | 102 | Two-stage | 5 years | 98.2% |
| Raes et al. 2018 | IIP16 DIP23 | Two-stage | 96 months | IIP 93.8% DIP 100% |
| Tonetti et al. 2017 | 124 | Two-stage | 1 year to 3 years | 98% |
| Zuiderveld et al. 2018 | 60 | One-stage | 12 months | 96.7% |

Table S4. Soft tissue outcomes.

| Study | Approach | F/U periods | Periodontal (soft tissue) outcomes | | | |
|-------|----------|-------------|------------------------------------|---------|---------|--------|
| | | | Gingival recession (mm) | BOP (%) | PD (mm) | PI (%) |
| | | | | | | |

| | | | | | | |
|-----------------------|-----------|---------------------|---|---|---------------|---------------|
| Arora et al. 2017 | One-stage | 2-5 years | 0.29 ± 0.74 Mesial: 0.05 ± 0.64 Distal: 0.16 ± 0.63 | X | X | X |
| Baer et al. 2013 | One-stage | 6 months to 3 years | X | 6 months: 14.28% 1 year: 11.54% 2 years: 8.51% 3 years: 14.58% | X | X |
| Cosyn et al. 2011 | One-stage | 3 years | 0.34 (-2.0 to 1.0) | 24% | 3.17 | 18% |
| Guarnieri et al. 2015 | One-stage | 5 years | 0.1 ± 0.61 | X | X | X |
| Meijer et al. 2019 | One-stage | 12 months | 0.5 ± 0.6 | X | X | X |
| Meloni et al. 2020 | One-stage | 5 years | X | X 8 | 2.40-2.5 | X |
| Oliver 2012 | One-stage | 12 months | 0.1 ± 0.3 | X | 2.1 ± 0.7 | X |
| Canullo et al. 2010 | Two-stage | 3 years | 0.76-0.98 | 0.55-0.61 0 | 2.75-2.8 0 | 1.34-1.6 7 |
| Cooper et al. 2014 | Two-stage | 5 years | Mesial: 0.13 ± 1.61 Distal: 0.21 ± 1.61 | 6.6-7.2% | X | X |
| Cucchi et al. 2017 | Two-stage | 3 years | X | 9.4-13.6 % | X | X |
| Raes et al. 2018 | Two-stage | 96 months | Mesial 0.44 ± 1.04 Distal: 0.27 ± 0.55 | 18.2% | 2.7 ± 0.5 | X |
| Tonetti et al. 2017 | Two-stage | 1 to 3 years | X | X | 3.3-4.1 | X |

Table S5. Hard tissue outcomes.

| Study | Approach | F/U periods | Marginal bone loss (MBL, mm) |
|-----------------------------|-----------|-------------|--|
| Aguirre-Zorzano et al. 2011 | One-stage | 92 weeks | Mesial: 0.2 ± 0.4 mm Distal: 0.2 ± 0.4 mm |

| | | | |
|------------------------|-----------|--------------------------|--|
| Arora et al. 2017 | One-stage | 2-5 years | Mesial: -0.18 ± 1.38 mm Distal: -0.34 ± 1.40 mm |
| Baer et al. 2013 | One-stage | 6 months to 3 years | 6 months: -1.02 ± 1.12 mm 1 year: -1.12 ± 1.16 mm 2 years: -1.26 ± 1.32 mm 3 years: -1.07 ± 1.40 mm |
| Carinci 2012 | One-stage | 7 months | 0.2 ± 0.7 mm |
| Cosyn et al. 2011 | One-stage | 3 years | 1mm (1.13 mm in mesial bone, 0.86 mm in distal bone) |
| Covani et al. 2012 | One-stage | 10 years | 0.6 to 1.5 mm |
| Gamper et al. 2017 | One-stage | 4-6 years | 0.51-1.02 |
| Guarnieri et al. 2015 | One-stage | 5 years | 0.98 ± 0.5 mm |
| Meloni et al. 2020 | One-stage | 5 years | 1.24 ± 0.39 mm |
| Naeini et al. 2018 | One-stage | 6-9 years (88 months) | (-0.89)-0.49 mm |
| Oliver 2012 | One-stage | 12 months | 0.3 ± 0.4 mm |
| Zuiderveld et al. 2018 | One-stage | 12 months | Mesial: 0.05 ± 0.44 mm Distal: 0.025 ± 0.375 mm |
| Atieh et al. 2013 | Two-stage | 1 year | -0.41 ± 0.57 mm |
| Canullo et al. 2010 | Two-stage | 3 years | 0.34-0.55 mm |
| Cooper et al. 2014 | Two-stage | 5 years | -2.06 ± 2.38 mm |
| Corvino et al. 2020 | Two-stage | 6 months to 1 year | 6 months: 0.33-0.43 mm 1 year: 0.48-0.57 mm |
| Cucchi et al. 2017 | Two-stage | 3 years | 0.4-0.5 mm |
| Esposito et al. 2015 | Two-stage | 4 months to 12 months | (-0.27)-(-0.13) mm |
| Felice et al. 2015 | Two-stage | 4 months to 12 months | (-0.19)-(-0.13) mm |
| Negri et al. 2014 | Two-stage | 36 months | 0.8 ± 0.03 mm |
| Raes et al. 2018 | Two-stage | 96 months | (-0.98)-0.49 mm |